A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01516918
Recruitment Status : Completed
First Posted : January 25, 2012
Last Update Posted : October 20, 2014
Information provided by (Responsible Party):
Vertex Pharmaceuticals Incorporated

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : September 2013
  Study Completion Date : December 2013
  Certification/Extension First Submitted : October 9, 2014